| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
Bryhali is owned by Bausch.
Bryhali contains Halobetasol Propionate.
Bryhali has a total of 2 drug patents out of which 0 drug patents have expired.
Bryhali was authorised for market use on 06 November, 2018.
Bryhali is available in lotion;topical dosage forms.
Bryhali can be used as topical treatment of plaque psoriasis in adults.
The generics of Bryhali are possible to be released after 02 November, 2031.
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2018
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
BRYHALI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic